Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025
Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid management, has announced the postponement of its Q2 2025 earnings release and conference call from August 12 to August 14, 2025.
The delay is attributed to the company requiring additional time for completing valuations and allowing their auditor, Baker Tilly US, LLP, to finish related audit procedures. The company clarified there are no disagreements with their auditor. The rescheduled conference call will take place at 9:00 AM ET on August 14, with both webcast and dial-in options available for investors.
Nuwellis (Nasdaq: NUWE), un'azienda di tecnologia medica specializzata nella gestione dei fluidi, ha annunciato il rinvio della pubblicazione dei risultati del secondo trimestre 2025 e della conference call, originariamente prevista per il 12 agosto, al 14 agosto 2025.
Il ritardo 猫 dovuto alla necessit脿 di pi霉 tempo per completare le valutazioni e permettere al revisore contabile, Baker Tilly US, LLP, di terminare le procedure di audit correlate. L'azienda ha precisato che non vi sono disaccordi con il revisore. La conference call riprogrammata si terr脿 alle 9:00 AM ET del 14 agosto, con opzioni di webcast e chiamata telefonica disponibili per gli investitori.
Nuwellis (Nasdaq: NUWE), una empresa de tecnolog铆a m茅dica especializada en la gesti贸n de fluidos, ha anunciado el aplazamiento de su publicaci贸n de resultados del segundo trimestre de 2025 y la conferencia telef贸nica del 12 de agosto al 14 de agosto de 2025.
El retraso se debe a que la compa帽铆a necesita m谩s tiempo para completar las valoraciones y permitir que su auditor, Baker Tilly US, LLP, finalice los procedimientos de auditor铆a relacionados. La empresa aclar贸 que no existen desacuerdos con su auditor. La conferencia telef贸nica reprogramada tendr谩 lugar a las 9:00 AM ET del 14 de agosto, con opciones de webcast y llamada disponibles para los inversores.
Nuwellis (雮橃姢雼�: NUWE)電� 觳挫暋 甏�毽棎 韸鬼檾霅� 鞚橂 旮办垹 須岇偓搿�, 2025雲� 2攵勱赴 鞁れ爜 氚滍憸 氚� 旎嵓霟办姢 旖�鞚� 8鞗� 12鞚检棎靹� 2025雲� 8鞗� 14鞚�搿� 鞐瓣赴頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
鞚措矆 鞐瓣赴電� 須岇偓臧� 韽夑皜 鞛戩梾鞚� 鞕勲頃橁碃 臧愳偓鞚胳澑 Baker Tilly US, LLP臧� 甏�霠� 臧愳偓 鞝堨皑毳� 毵堨範 鞁滉皠鞚� 雿� 頃勳殧搿� 頃橁赴 霑岆鞛呺媹雼�. 須岇偓 旄§潃 臧愳偓鞚戈臣鞚� 鞚搓铂鞚� 鞐嗢潓鞚� 氇呿檿頌� 頄堨姷雼堧嫟. 鞐瓣赴霅� 旎嵓霟办姢 旖滌潃 8鞗� 14鞚� 霃欕秬鞁滉皠 鞓れ爠 9鞁�鞐� 歆勴枆霅橂┌, 韴瀽鞛愲摛鞚� 鞙勴暣 鞗轨簮鞀ろ姼鞕� 鞝勴檾 鞝戩啀 鞓奠厴鞚� 鞝滉车霅╇媹雼�.
Nuwellis (Nasdaq : NUWE), une entreprise de technologie m茅dicale sp茅cialis茅e dans la gestion des fluides, a annonc茅 le report de sa publication des r茅sultats du deuxi猫me trimestre 2025 et de la conf茅rence t茅l茅phonique du 12 ao没t au 14 ao没t 2025.
Ce retard est d没 au fait que la soci茅t茅 a besoin de temps suppl茅mentaire pour finaliser les 茅valuations et permettre 脿 son auditeur, Baker Tilly US, LLP, de terminer les proc茅dures d'audit associ茅es. La soci茅t茅 a pr茅cis茅 qu'il n'y a aucun d茅saccord avec son auditeur. La conf茅rence t茅l茅phonique reprogramm茅e aura lieu 脿 9h00 ET le 14 ao没t, avec des options de webdiffusion et de t茅l茅phone pour les investisseurs.
Nuwellis (Nasdaq: NUWE), ein Medizintechnikunternehmen, das sich auf Fl眉ssigkeitsmanagement spezialisiert hat, hat die Verschiebung der Ver枚ffentlichung der Ergebnisse f眉r das zweite Quartal 2025 und der Telefonkonferenz vom 12. August auf den 14. August 2025 bekannt gegeben.
Die Verz枚gerung ist darauf zur眉ckzuf眉hren, dass das Unternehmen zus盲tzliche Zeit ben枚tigt, um Bewertungen abzuschlie脽en und seinem Wirtschaftspr眉fer Baker Tilly US, LLP die Fertigstellung der zugeh枚rigen Pr眉fungsverfahren zu erm枚glichen. Das Unternehmen stellte klar, dass es keine Meinungsverschiedenheiten mit dem Pr眉fer gibt. Die neu terminierte Telefonkonferenz findet am 14. August um 9:00 Uhr ET statt, wobei Investoren sowohl Webcast- als auch Einwahll枚sungen zur Verf眉gung stehen.
- None.
- Delay in financial reporting indicates potential complexities in valuation processes
- Additional time needed for audit procedures suggests possible accounting complexities
MINNEAPOLIS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced that it will postpone its 2025 second quarter earnings release and conference call, originally scheduled for August 12, 2025. The Company requires additional time to complete its valuations and for its audit firm to complete its related audit procedures. There are no current disagreements with Baker Tilly US, LLP, the Company鈥檚 auditor. The Company expects to host a conference call and webcast at 9:00 AM ET on August 14, 2025 to discuss its financial results and provide a general business update.
To access the live webcast, please visit the Investors page of the Nuwellis website at聽. Alternatively, you may access the live conference call by dialing 1-800-245-3047 (U.S) or 1-203-518-9765 (international) and using the conference ID: NUWEQ2. An audio archive of the webcast will be available following the call on the Investors page at聽.
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow庐 system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
About the Aquadex SmartFlow庐 System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, revenues, earnings, strategies, statements regarding new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
Robert Scott
Chief Financial Officer
Media Contact:
Leah McMullen
Director of Communications
FAQ
Why did Nuwellis (NUWE) postpone its Q2 2025 earnings release?
When is the new date for Nuwellis (NUWE) Q2 2025 earnings call?
How can investors access Nuwellis (NUWE) Q2 2025 earnings call?
Is there any conflict between Nuwellis and its auditor regarding the Q2 2025 earnings delay?
